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Abstract Given the increasing aetiological importance of
Streptococcus dysgalactiae subspecies equisimilis in diseases
which are primarily attributed to S. pyogenes, molecular
markers are essential to distinguish these species and
delineate their epidemiology more precisely. Many clinical
microbiology laboratories rely on agglutination reactivity
and biochemical tests to distinguish them. These methods
have limitations which are particularly exacerbated when
isolates with mixed properties are encountered. In order to
provide additional distinguishing parameters that could be
used to unequivocally discriminate these two common
pathogens, we assess here three molecular targets: the speB
gene, intergenic region upstream of the scpG gene (IRSG)
and virPCR. Of these, the former two respectively gave
positive and negative results for S. pyogenes, and negative
and positive results for S. dysgalactiae subsp. equisimilis.
Thus, a concerted use of these nucleic acid-based methods is
particularly helpful in epidemiological surveillance to accu-
rately assess the relative contribution of these species to
streptococcal infections and diseases.
Introduction
Streptococcus pyogenes and S. dysgalactiae subspecies
equisimilis are closely related Gram-positive bacteria that
colonise the skin and respiratory tract of humans. S. pyogenes
infection is associated with a wide range of diseases, which
include relatively benign and common diseases (such as
bacterial pharyngitis, impetigo and scarlet fever), potentially
fatal invasive diseases (such as necrotising fasciitis and toxic
shock syndrome) and rheumatic heart disease [1]. Together,
these diseases are estimated to kill half a million people each
year [2]. S. dysgalactiae subsp. equisimilis, which occupies
the same tissue sites as S. pyogenes, was previously
considered to be a less pathogenic organism and causes
infections opportunistically [3]. S. dysgalactiae subsp.
equisimilis expresses many of the same virulence factors
(including the M-protein, C5a peptidase, streptokinase,
fibronectin binding proteins and plasminogen receptors) as
those expressed by S. pyogenes [4–9] and can cause a similar
spectrum of diseases in humans as S. pyogenes [3, 10, 11].
In many populations, the S. dysgalactiae subsp. equisimilis
colonisation rate in the throat and the rate of its recovery
from pharyngitis exceed that of S. pyogenes [12]. The relative
contribution by these species to the disease burden could
vary considerably between communities and populations
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[13, 14]. There is a paucity of information on streptococcal
disease burden in many resource-poor nations [15]. The lack
of definitive and rapid tests to differentiate these species and
the perception among clinicians that S. dysgalactiae subsp.
equisimilis is generally non-pathogenic may also have
contributed to this paucity. Recent studies on invasive
disease due to beta-haemolytic streptococci of groups other
than A and B concluded distinct clinical manifestations in
some populations [16–18]. These studies recommended
increased awareness of S. dysgalactiae subsp. equisimilis as
a human pathogen and emphasise the importance of the
identification of beta-haemolytic streptococci at the species
level.
It is generally difficult to distinguish S. pyogenes and
S. dysgalactiae subsp. equisimilis on a morphological basis,
as both species are usually large colony forming with similar
haemolysis patterns. These and other beta-haemolytic strepto-
cocci are traditionally differentiated on the basis of differences
in carbohydrate on the bacterial surface and sensitivity to
bacitracin [19]. Additional diagnostics such as the PYR
reaction (for L-pyrrolidonyl-β-naphthylamide aminopepti-
dase) may be used as confirmatory tests, but are not routine
procedures in many clinical microbiology laboratories.
Whereas the group A carbohydrate is found in S. pyogenes,
it has also been found in S. dysgalactiae subsp. equisimilis in
rare cases [5, 20]. Positive reactivity to group C or G antigen
is given by S. dysgalactiae subsp. equisimilis, S. dysgalactiae
subsp. dysgalactiae, S. equi, S. canis and S. anginosus [5, 20,
21]. The bacitracin sensitivity test can sometimes give false-
positive results [19]. While the PYR test has excellent
specificity and sensitivity in discriminating S. pyogenes from
S. dysgalactiae subsp. equisimilis, other bacteria commonly
found in the same habitat may also give a positive reaction
[22], and the test performed less well in routine diagnostic
laboratory settings, sometimes giving weaker reactions [23].
In order to provide additional distinguishing parameters that
could be used to discriminate these species, we assess here
three molecular targets.
Materials and methods
S. pyogenes and S. dysgalactiae subsp. equisimilis isolates
were collected from two different geographical regions,
India and Australia. The three isolates with unusual
characteristics were from Europe. The bacteria were grown
on Todd–Hewitt agar supplemented with 2% horse blood.
Group carbohydrates were determined using the Prolex
Streptococcal Grouping Latex Kit (Pro-Lab Diagnostics).
The PYR test was performed according to the manufac-
turer’s instructions (Becton Dickinson). DNAwas extracted
using purification kits (QIAGEN Inc.). The polymerase
chain reaction (PCR) conditions were as follows. For speB:
denaturation 94°C/30 s, annealing 55°C/30 s, extension 72°C/
90 s; forward and reverse primers were GGTTCTGCAGG
TAGCTCTCG and TGCCTACAACAGCACTTTGG. For
the intergenic region upstream of the scpG gene (IRSG): the
conditions were the same as above and the primers were
CAACACATAACCACCTTCTGGA and TTGCAAGTGCG
TCACAAGAT. The primers and conditions for virPCR were
as described previously [24, 25]. Sequence typing (emm
typing) was performed as described by Beall et al. [26] and
sequencing the gene for rRNA was carried out after
amplifying with universal primers [27].
Results and discussions
The rationales for the selection of the targets are as follows.
Comparative microarray analysis showed that the gene
encoding streptococcal cysteine protease, speB, found
ubiquitously in S. pyogenes isolates [28, 29], is absent in
S. dysgalactiae subsp. equisimilis [30]. Furthermore, a speB
orthologue has not been reported in other bacteria. Hence,
the PCR primers targeting this gene are expected to be
specific for S. pyogenes. Indeed, a PCR for speB has been
suggested as a diagnostic test for the S. pyogenes aetiology
of necrotising fasciitis [31]. The remaining two targets are
based on the sequence differences in S. pyogenes and S.
dysgalactiae subsp. equisimilis upstream of the gene for
C5a peptidase (scpA and scpG, respectively). The physical
locations of scpA, emm (gene for M protein) and the
regulator mga in the S. pyogenes genome are close to each
other and are amplifiable by PCR (virPCR; [24, 25]).
Depending on the architecture of this chromosomal region,
the amplicon arising from virPCR is about 4–7 kb. All
S. dysgalactiae subsp. equisimilis isolates possess emm and
scpG genes [10, 32]. However, previous studies [7, 33]
revealed that the emm and scpG genes in the S. dysgalactiae
subsp. equisimilis genome are not physically linked and the
Fig. 1 Organisation of the intergenic region upstream of scpG (IRSG)
of Streptococcus dysgalactiae subsp. equisimilis. The virPCR primers
(dashed arrows) and the IRSG primers (solid arrows) are shown. The
length virPCR amplifiable region is somewhat variable, but in more
than 98% of S. dysgalactiae subsp. equisimilis isolates, it is about
2 kb. Within this region, the segment defined by IRSG PCR primers is
highly conserved and targets a hypothetical protein
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sequences immediately upstream of scpG exhibit mosaic
structure [34]. However, the virPCR designed for S. pyogenes
also gave a product with S. dysgalactiae subsp. equisimilis,
but the amplicon was only about 2 kb [33–35], suggesting
that the primer binding sites may be conserved.We sequenced
the virPCR products from diverse S. dysgalactiae subsp.
equisimilis strains and found that an open reading frame for a
hypothetical protein within the IRSG is highly conserved in
all of the strains (Fig. 1) and is absent in S. pyogenes. This
allowed us to design S. dysgalactiae subsp. equisimilis-
specific IRSG PCR primers.
S. pyogenes (n=58) and S. dysgalactiae subsp. equisimilis
(n=109) isolates in this study belong to 41 and 36 distinct
emm (sub)types, respectively, suggesting that they are highly
diverse (Table 1). The collection also represents multiple
isolates of the same emm type. We have shown previously
that horizontal gene transfers mediated by phages and
conjugative transposons between these species are ongoing
events and occur with greater frequencies among isolates
from highly endemic regions [35]. Therefore, it is all the
more necessary to show species-specific distribution of the
target genes among the isolates from highly endemic
regions. Clonal diversity and two distinct geographical
sources of isolates, one of them (India) being highly
endemic for streptococcal infection, fulfil the requirement
in this regard.
All of the strains listed in Table 1 were beta-haemolytic
on blood agar plates and possessed group A, C or G
carbohydrate. The isolates expressing group A carbohydrate
were PYR-positive, and the isolates expressing the group C or
G antigen were PYR-negative. All of the isolates presump-
tively identified as S. pyogenes based on the above reactions
were positive for the speB amplicon, whereas none of the
S. dysgalactiae subsp. equisimilis isolates were positive for
this reaction. The IRSG assay also proved highly discrimi-
natory, as all S. dysgalactiae subsp. equisimilis isolates tested
produced the expected product of about 500 bp, and none of
the S. pyogenes isolates gave this amplicon. All PCRs were
performed with appropriate positive controls and template-
negative controls. Thus, speB and IRSG PCRs together
unequivocally distinguish S. pyogenes and S. dysgalactiae
subsp. equisimilis.
As reported earlier, the virPCR gave products with both
the S. pyogenes and S. dysgalactiae subsp. equisimilis
isolates in this study (Table 1). As expected, DNA from all
of the S. pyogenes isolates gave approximately 4–7-kb
product. By contrast, the reaction gave approximately 2-kb
products from 107 of the 109 S. dysgalactiae subsp.
equisimilis isolates. One S. dysgalactiae subsp. equisimilis
isolate yielded a 3-kb product and another a 4-kb product.
Both of these isolates expressed group C carbohydrate.
Sequence analysis of these variant virPCR products (data
not shown) revealed insertions within the mosaic regions
upstream of the C5a peptidase gene. However, the region of
the hypothetical open reading frame targeted by the IRSG
primers is conserved (Fig. 1).
Ongoing cross-species horizontal gene transfers [33, 35,
36] could give rise to isolates with mixed characteristics. In
this study, three isolates with mixed characteristics were
tested. Two isolates (2005-0193 and 2006-0098) that were
S. dysgalactiae subsp. equisimilis as judged by negative
reaction to the PYR test but showed agglutination reaction
with the group A reagent were also tested by PCRs
(Table 2). Both were positive for IRSG PCR and negative
for speB PCR. The size of the virPCR amplicons were 2 kb.
We further confirmed the identity of these isolates as
S. dysgalactiae subsp. equisimilis by 16S rRNA gene
sequencing (data not shown). Another isolate (2007-0217)
was S. pyogenes as shown by PYR positivity, group A
carbohydrate reactivity and rRNA gene sequence. However,
2007-0217 belonged to emm stg1750, a type normally found
in S. dysgalactiae subsp. equisimilis, suggesting horizontal
transfer of the emm gene. This isolate was speB-positive and
IRSG-negative (Table 2). Furthermore, the virPCR product is
7 kb long and revealed physical proximity of the emm locus
to the scpA gene (data not shown).
Group
carbohydrate
Number
of isolates
Number of emm
types or subtypes
PYR
test
IRSG
PCR
speB
PCR
virPCR size (kb)
∼2 3 4 >4–7
A 58 41 + − + 0 0 1 57
G 98 31 − + − 98 0 0 0
C 11 5 − + − 9 1 1 0
Table 1 Molecular and
biochemical tests carried
out on 167 S. pyogenes
and S. dysgalactiae subsp.
equisimilis isolates from
Australia and India
Strain name Group carbohydrate emm type PYR test IRSG PCR speB PCR virPCR (kb)
2005-0193 A stg6 − + − ∼2
2006-0098 A stg6 − + − ∼2
2007-0217 A stg1750 + − + ∼7
Table 2 Molecular and
biochemical tests carried out
on three unusual S. pyogenes
and S. dysgalactiae subsp.
equisimilis isolates
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Recently, a real-time PCR and a low-density microarray
were developed to distinguish S. pyogenes and S. dysgalactiae
subsp. equisimilis. These assays are based on a common target
for both species and another one specific for S. pyogenes [37].
The authors recognised that their diagnostic system does not
have a positive test for S. dysgalactiae subsp. equisimilis. By
choosing specific targets for each of the species (speB and
IRSG PCRs for S. pyogenes and S. dysgalactiae subsp.
equisimilis, respectively), we have overcome this limitation. It
may be noted that none of the molecular markers thus far
described differentiate between group G and C carbohydrate
expressing S. dysgalactiae subsp. equisimilis, suggesting that
the acquisition of differences in group carbohydrate may have
preceded that of molecular markers.
In summary, the three PCRs proposed here offer
excellent discriminatory power in identifying common
beta-haemolytic streptococcal human pathogens. The tests
could be particularly useful in epidemiological surveillance
to accurately assess the relative contribution of S. pyogenes
and S. dysgalactiae subsp. equisimilis to streptococcal
infections and diseases. Current clinical management of
infections owing to these species are not different, as both
have remained sensitive to penicillin. However, resistance
to fluoroquinolone in S. pyogenes has been found to be
horizontally acquired from S. dysgalactiae [38, 39].
Horizontal gene transfers have the ability to rapidly change
in population structure, which, in turn, may require tailored
management in the future. In the light of these observations,
we believe that it would be prudent to identify the definitive
aetiology of streptococcal infections and diseases.
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